

---

# Contents

<i>Preface</i> . . . . .	<i>v</i>
<i>Contributors</i> . . . . .	<i>xv</i>
1 Small Molecule Formulation Screening Strategies in Drug Discovery. . . . . <i>Gary W. Caldwell, Becki Hasting, John A. Masucci, and Zhengyin Yan</i>	1
2 Assessment of Drug Plasma Protein Binding in Drug Discovery. . . . . <i>Dennis Kalamaridis and Nayan Patel</i>	21
3 Drug Partition in Red Blood Cells. . . . . <i>Dennis Kalamaridis and Karen DiLoreto</i>	39
4 Permeability Assessment Using 5-day Cultured Caco-2 Cell Monolayers . . . . . <i>Gary W. Caldwell, Chrissa Ferguson, Robyn Buerger, Lovonia Kulp, and Zhengyin Yan</i>	49
5 In Situ Single Pass Perfused Rat Intestinal Model . . . . . <i>Maria Markowska and L. Mark Kao</i>	77
6 Metabolic Stability Assessed by Liver Microsomes and Hepatocytes. . . . . <i>Kevin J. Coe and Tatiana Koudriakova</i>	87
7 Metabolic Assessment in Alamethicin-Activated Liver Microsomes: Co-activating CYPs and UGTs . . . . . <i>Gary W. Caldwell and Zhengyin Yan</i>	101
8 Phenotyping UDP-Glucuronosyltransferases (UGTs) Involved in Human Drug Metabolism: An Update . . . . . <i>Michael H. Court</i>	117
9 In Vitro CYP/FMO Reaction Phenotyping. . . . . <i>Carlo Sensenhauser</i>	137
10 Human Pregnane X Receptor (hPXR) Activation Assay in Stable Cell Lines . . . . . <i>Judy L. Raucy</i>	171
11 Characterization of Constitutive Androstane Receptor (CAR) Activation. . . . . <i>Caitlin Lynch, Haishan Li, and Hongbing Wang</i>	195
12 DNA Binding (Gel Retardation Assay) Analysis for Identification of Aryl Hydrocarbon (Ah) Receptor Agonists and Antagonists. . . . . <i>Anatoly A. Soshilov and Michael S. Denison</i>	207
13 Cell-Based Assays for Identification of Aryl Hydrocarbon Receptor (AhR) Activators. . . . . <i>Guochun He, Jing Zhao, Jennifer C. Brennan, Alessandra A. Affatato, Bin Zhao, Robert H. Rice, and Michael S. Denison</i>	221

14	In Vitro CYP Induction Using Human Hepatocytes . . . . .	237
	<i>Monica Singer, Carlo Sensenhauser, and Shannon Dallas</i>	
15	Assessment of CYP3A4 Time-Dependent Inhibition in Plated and Suspended Human Hepatocytes. . . . .	255
	<i>J. George Zhang and David M. Stresser</i>	
16	Evaluation of Time-Dependent CYP3A4 Inhibition Using Human Hepatocytes. . . . .	269
	<i>Yuan Chen and Adrian J. Fretland</i>	
17	Rapidly Distinguishing Reversible and Time-Dependent CYP450 Inhibition Using Human Liver Microsomes, Co-incubation, and Continuous Fluorometric Kinetic Analyses . . . . .	281
	<i>Gary W. Caldwell and Zhengyin Yan</i>	
18	Identification of Time-Dependent CYP Inhibitors Using Human Liver Microsomes (HLM) . . . . .	305
	<i>Kevin J. Coe, Judith Skaptason, and Tatiana Koudriakova</i>	
19	CYP Time-Dependent Inhibition (TDI) Using an IC <sub>50</sub> Shift Assay with Stable Isotopic Labeled Substrate Probes to Facilitate Liquid Chromatography/Mass Spectrometry Analyses . . . . .	315
	<i>Gary W. Caldwell and Zhengyin Yan</i>	
20	Screening for P-Glycoprotein (Pgp) Substrates and Inhibitors . . . . .	337
	<i>Qing Wang and Tina M. Sauerwald</i>	
21	In Vitro Characterization of Intestinal Transporter, Breast Cancer Resistance Protein (BCRP) . . . . .	353
	<i>Chris Bode and Li-Bin Li</i>	
22	In Vitro Characterization of Intestinal and Hepatic Transporters: MRP2 . . . . .	369
	<i>Ravindra Varma Alluri, Peter Ward, Jeevan R. Kunta, Brian C. Ferslew, Dhiren R. Thakker, and Shannon Dallas</i>	
23	In Vitro Characterization of Hepatic Transporters OATP1B1 and OATP1B3 . . . . .	405
	<i>Blair Mieczewski and Allison McLaughlin</i>	
24	In Vitro Characterization of Renal Transporters OAT1, OAT3, and OCT2 . . .	417
	<i>Ying Wang and Nicole Behler</i>	
25	General Guidelines for Setting Up an In Vitro LC/MS/MS Assay . . . . .	431
	<i>John A. Masucci and Gary W. Caldwell</i>	
26	Metabolite Identification in Drug Discovery . . . . .	445
	<i>Wing W. Lam, Jie Chen, Rongfang Fran Xu, Jose Silva, and Heng-Keang Lim</i>	
27	Drug, Lipid, and Acylcarnitine Profiling Using Dried Blood Spot (DBS) Technology in Drug Discovery. . . . .	461
	<i>Wensheng Lang, Jenson Qi, and Gary W. Caldwell</i>	
28	In Vitro Trapping and Screening of Reactive Metabolites Using Liquid Chromatography-Mass Spectrometry. . . . .	477
	<i>Zhengyin Yan and Gary W. Caldwell</i>	

29	Quantitative Assessment of Reactive Metabolites . . . . .	489
	<i>Jie Chen, Rongfang Fran Xu, Wing W. Lam, Jose Silva, and Heng-Keang Lim</i>	
30	In Vitro Assessment of the Reactivity of Acyl Glucuronides . . . . .	505
	<i>Rongfang Fran Xu, Wing W. Lam, Jie Chen, Michael McMillian, Jose Silva, and Heng-Keang Lim</i>	
31	In Vitro Comet Assay for Testing Genotoxicity of Chemicals. . . . .	517
	<i>Haixia Lin, Nan Mei, and Mugimane G. Manjanatha</i>	
32	Assessing DNA Damage Using a Reporter Gene System . . . . .	537
	<i>Michael Biss and Wei Xiao</i>	
33	Improved AMES Test for Genotoxicity Assessment of Drugs: Preincubation Assay Using a Low Concentration of Dimethyl Sulfoxide. . . . .	545
	<i>Atsushi Hakura</i>	
34	Methods for Using the Mouse Lymphoma Assay to Screen for Chemical Mutagenicity and Photo-Mutagenicity. . . . .	561
	<i>Nan Mei, Xiaoqing Guo, and Martha M. Moore</i>	
	<i>Index</i> . . . . .	593